Authors

• Jonathan Thorsen (ORCID: https://orcid.org/0000-0003-0200-0461)
• Agoston Gyula Szabo (ORCID: https://orcid.org/0000-0001-9943-7007)
• Cecilie Blimark (ORCID: https://orcid.org/0000-0003-3297-6019)
• Ain Kaare (ORCID: https://orcid.org/0000-0002-3170-1016)
• Anna Lysén
• Dorota Knut‐Bojanowska
• Katrin Palk
• Valdas Pečeliūnas (ORCID: https://orcid.org/0000-0001-8232-8381)
• Jakob N. Norgaard
• Sigrún Þorsteinsdóttir (ORCID: https://orcid.org/0000-0001-5017-3530)
• Vilmantė Vaitekėnaitė (ORCID: https://orcid.org/0000-0001-8949-3902)
• Sæmundur Rögnvaldsson (ORCID: https://orcid.org/0000-0003-2162-8414)
• Annette Juul Vangsted (ORCID: https://orcid.org/0000-0002-2131-731X)
• Fredrik Schjesvold (ORCID: https://orcid.org/0000-0003-1096-0569)
• Kari Lenita Falck Moore (ORCID: https://orcid.org/0000-0002-2190-2762)
• Diana Loigom
• Maris Pärnat
• Alexander Sigurdsson
• Anna Genell
• Nordic Myeloma Study Group

Institutions

• Reykjavík University (IS)
• Oslo University Hospital (NO)
• University of Iceland (IS)
• Vilnius University (LT)
• University of Oslo (NO)
• Stavanger University Hospital (NO)
• Sahlgrenska University Hospital (SE)
• Tartu University Hospital (EE)
• Copenhagen University Hospital (DK)
• Rigshospitalet (DK)
• Vejle Sygehus (DK)
• North Estonia Medical Centre (EE)
• National University Hospital of Iceland (IS)
• Copenhagen Prospective Studies on Asthma in Childhood (DK)
• Uddevalla sjukhus (SE)
• National Cancer Institute (LT)
• Reykjavík Energy (Iceland) (IS)
• University of Gothenburg (SE)

Publication Details

Journal

Haematologica

Published

2025-09-04

DOI

https://doi.org/10.3324/haematol.2025.287344

Primary Topic

Multiple Myeloma Research and Treatments

Type

article

Field-Weighted Citation Impact

0.00

Funders

• Pfizer
• AstraZeneca
• Sanofi